Industry Input Will Bolster Risk-Based Inspection Approach – FDA’s Ellsworth
This article was originally published in The Tan Sheet
Executive Summary
FDA is "hoping" to use future facility inspections to compile data that will strengthen the "process risk" prong of its risk-based site selection model by gaining knowledge about quality systems currently in use by industry, according to New Jersey District Director Douglas Ellsworth
You may also be interested in...
Experts Address Chondroitin Testing In Wake Of ConsumerLab Report
Results of a recent ConsumerLab.com report on joint supplements that found 7 out of 11 tested products contained less chondroitin than stated on the label did not surprise experts in the industry
Experts Address Chondroitin Testing In Wake Of ConsumerLab Report
Results of a recent ConsumerLab.com report on joint supplements that found 7 out of 11 tested products contained less chondroitin than stated on the label did not surprise experts in the industry
Experts Address Chondroitin Testing In Wake Of ConsumerLab Report
Results of a recent ConsumerLab.com report on joint supplements that found 7 out of 11 tested products contained less chondroitin than stated on the label did not surprise experts in the industry